Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersNo recent work listed

Jantien A. Vogel

Matched on ORCID iD 0000-0002-7019-1960; OpenAlex author ID A5058218015. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper

Papers 10

  1. Quantitative analysis of contribution of mild and moderate hyperthermia to thermal ablation and sensitization of irreversible electroporation of pancreatic can… Co-author DOI 10.1016/j.jtherbio.2023.103619↗
  2. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison. Co-author DOI 10.1016/j.jvir.2020.02.024↗
  3. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Co-author DOI 10.3390/cancers11070976↗
  4. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. First author DOI 10.1002/bjs.10870↗
  5. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. First author DOI 10.1016/j.hpb.2018.01.001↗
  6. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. Co-author DOI 10.1148/radiol.2016152835↗
  7. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Co-author DOI 10.1245/s10434-017-5900-9↗
  8. Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. Co-author DOI 10.1016/j.path.2016.05.002↗
  9. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5373-2↗
  10. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. First author DOI 10.1002/bjs.9716↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 10 shared papers, 2015–2023 · strength 0.78
  2. Krijn P. van Lienden · 6 shared papers, 2015–2023 · strength 0.53
  3. Johanna W. Wilmink · 6 shared papers, 2016–2020 · strength 0.45
  4. Eran van Veldhuisen · 4 shared papers, 2018–2023 · strength 0.42
  5. Izaak Quintus Molenaar · 4 shared papers, 2015–2019 · strength 0.24
  6. Steffi J. E. Rombouts · 4 shared papers, 2015–2017 · strength 0.23
  7. Martijn Ruben Meijerink · 3 shared papers, 2017–2020 · strength 0.23
  8. Casper H.J. van Eijck · 3 shared papers, 2016–2019 · strength 0.21
  9. Marieke S. Walma · 3 shared papers, 2016–2019 · strength 0.19
  10. Hjalmar C. van Santvoort · 3 shared papers, 2015–2019 · strength 0.19
  11. Pierre Agnass · 1 shared paper, 2023 · strength 0.17
  12. Johannes Crezee · 1 shared paper, 2023 · strength 0.17
  13. Geertjan van Tienhoven · 2 shared papers, 2018–2019 · strength 0.15
  14. Bas Groot Koerkamp · 2 shared papers, 2018–2019 · strength 0.15
  15. Hester J. Scheffer · 2 shared papers, 2017–2020 · strength 0.15
  16. Laurien G. P. H. Vroomen · 2 shared papers, 2017–2020 · strength 0.15
  17. Geert Kazemier M · 2 shared papers, 2017–2020 · strength 0.15
  18. Hanneke W.M. van Laarhoven · 2 shared papers, 2017–2018 · strength 0.14
  19. L. Bengt van Rijssen · 2 shared papers, 2016 · strength 0.11
  20. Alette H. Ruarus · 1 shared paper, 2020 · strength 0.09
  21. Sjors Klompmaker · 1 shared paper, 2018 · strength 0.08
  22. Hendrik A. Marsman · 1 shared paper, 2018 · strength 0.08
  23. Eva Versteijne · 1 shared paper, 2018 · strength 0.08
  24. Thilo Hackert · 1 shared paper, 2019 · strength 0.08
  25. Lilly J. H. Brada · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.